Loading...
•
Mar 31, 2024
NeoGenomics Q1 2024 Earnings Report
NeoGenomics experienced revenue growth and improved profitability in Q1 2024.
Key Takeaways
NeoGenomics reported a 14% increase in consolidated revenue to $156 million for Q1 2024. Clinical Services revenue increased by 17% to $135 million, while Advanced Diagnostics revenue decreased by 3% to $22 million. The company's adjusted EBITDA was positive at $3 million, a $11 million increase compared to the previous year. Net loss decreased by 12% to $27 million.
Consolidated revenue increased 14% to $156 million.
Clinical Services revenue increased 17% to $135 million.
Advanced Diagnostics revenue decreased 3% to $22 million.
Adjusted EBITDA was positive $3 million, an increase of 149% or $11 million.
Forward Guidance
The Company reaffirmed its full-year 2024 guidance, initially issued on February 20, 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...